Fiche traitement
HIFU
Hospital de Transplante Doutor Euryclides de Jesus Zerbini • Cancer
Suivi actif
Non applicable
Résumé
HIFU est développé par Hospital de Transplante Doutor Euryclides de Jesus Zerbini. Le traitement est actuellement en Non applicable. Il est associé à Cancer. Son objectif thérapeutique principal est Traitement symptomatique. Le statut actuel est : suivi actif.
À vérifier
Traitement symptomatique
Non applicable
Hospital de Transplante Doutor Euryclides de Jesus Zerbini
Brazil
Prostate cancer (PCa) is the most prevalent non cutaneous cancer in occidental countries. In Brazil incidence was about sixty thousand new cases in 2016 and occupied second place as all cancer mortality, just behind lung cancer. Literature shows than younger patients tend to have more aggressive tumors rising cancer specific mortality scores. Main risk factors are age, life style (sedentary, high meat and fat intake) and family history (gene inheritance).
Besides vast advances in precocious tumors detection, challenges remain in the definition of the biological status of the tumor, which is highly variable and full of prognostic implications. PCa heterogeneity is demonstrated by the uncertain natural history, varying from indolent lesion to aggressive metastatic and fast progression cancer resistant to conventional therapies. In an actual treatment scenario, prognostic identification is the cornerstone of daily practice treatment considering the natural history variability cited before and the discrepancy of long term slow growth (studies estimate eight to sixteen years of tumor growth to achieve metastatic disease) to high grade aggressive cancer.
Considering all this background and taking in account the indolent evolution of low risk PCa new therapies emerge with promising outcomes. High-Intensity Focused Ultrasound (HIFU) have to be highlighted due to easy operation, good oncologic results and low complication profile. The method is based on real-time imaging guided high intensity ultrasound (US) causing overheat and cavitation in the focused tissue. Applied since 90's, mainly in German and French groups, initially programmed to treat hole gland preserving only urinary sphincter and bladder neck, showed recently some data on 1700 patients, 5 years biochemical recurrence free survival of 80% and best results including morbidity profile in low risk, low prostate volume and in the group with previous trans urethral prostate resection (TURP). This results are very similar to other radical treatment options with median follow up of 8 years, cancer specific survival 98% and metastasis free survival of 95% If local recurrence was identified another HIFU ablation or even radical treatment achieved good results in local control with acceptable morbidity profile.
Focal treatment is a new entity in PCa therapy. One randomized trial compared focal treatment to active surveillance in 513 mans with PCa diagnosis. With a 24 month follow-up progression-free ratios (28% x 58%) and positive control prostate biopsy ratios (14% x 49%) were fairly superior in treatment group. This exiting novel data turns urological oncology paths to the new era of minimally harmful therapy with targeted focused procedure. At our knowledge there is no high evidence clinical trial comparing HIFU to active surveillance.
The objective of this study is to evaluate prospectively the initial experience with 50 patients submitted to HIFU therapy for low risk prostate cancer in Brazilian single center considering the following aspects:
One year of treatment prostate biopsy positiveness; Biochemical recurrence free survival using Phoenix and Stuttgart criteria in one year; Sexual function using IIEF-5 questionnaire and the usage of 5-phosphodiesterase inhibitors (5-PDI); Urinary symptoms using EPIC and IPSS questionnaires and free urinary flow; Quality of life based on SF-36 questionnaire evaluation; Post procedure morbidity using Clavien-Dindo classification.
2019-06-26
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Non applicable
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Traitement symptomatique
Confiance automatique : 87%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : progression → Ralentissement de la progression, symptom → Traitement symptomatique, bladder → Traitement symptomatique
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT03255135, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2019-06-26
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeStatut inconnu
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeNon applicable
Études associées1
Publications associées12
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
16 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2018-05-31 | Début de l’étudeNCT03255135 | Registre d’essai clinique |
| 2019-06-26 | Dernière mise à jour des donnéesHIFU | Biomedical Watch |
| 2019-07-01 | Fin de l’étude prévue / enregistréeNCT03255135 | Registre d’essai clinique |
| 2026-08-16 | PublicationDystonia before and after Unilateral High Intensity Focused Ultrasound Thalamotomy in Essential and Dystonic Tremor. | Movement disorders clinical practice |
| 2026-08-16 | PublicationDual-approach High-intensity Focused Ultrasound for Facial Contour Modulation and Submental Reduction. | Plastic and reconstructive surgery. Global open |
| 2026-08-16 | PublicationFocal Therapy for Prostate Cancer: A Treatment Option Reserved for the Ideal Candi-date? | International braz j urol : official journal of the Brazilian Society of Urology |
| 2026-08-16 | PublicationOncologic and functional outcomes of novel focal therapy methods for low-risk to intermediate-risk prostate cancer. | Current opinion in urology |
| 2026-08-16 | PublicationComparative study on the effects of high-intensity focused ultrasound (HIFU) and laparoscopic myomectomy on ovarian function and endometrial receptivity in patients with uterine fibroids. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group |
| 2026-08-16 | PublicationSafety, feasibility, and palliative benefit of HIFU combined with PD-1 inhibitors for elderly patients with advanced pancreatic cancer: a real-world retrospective study. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group |
| 2026-08-16 | PublicationNoninvasive treatment strategy for abdominal wall desmoid tumors applying high-intensity focused ultrasound. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group |
| 2026-08-16 | PublicationFast lesion mapping during HIFU treatment using harmonic motion imaging guided focused ultrasound (HMIgFUS) in vitro and in vivo. | Physics in medicine and biology |
| 2026-08-16 | PublicationApplication of high-intensity focused ultrasound in gynaecological diseases. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group |
| 2026-08-16 | PublicationMetabolic characteristic changes in local tissues after high-intensity focused ultrasound treatment for uterine fibroids. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group |
| 2026-09-01 | PublicationPhase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in stage IV breast cancer patients: study protocol of the i-GO study. | BMJ open |
| 2026-09-01 | PublicationMagnetic resonance imaging-guided ultrasound ablation for prostate cancer - A contemporary review of performance. | Frontiers in oncology |
| 2026-11-15 | Création de l’enregistrementNCT03255135 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT03255135 | Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes. | Non applicable | UNKNOWN | Brazil | Hospital de Transplante Doutor Euryclides de Jesus Zerbini |
Publications liées
12 publication(s)Publications liées
12 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in stage IV breast cancer patients: study protocol of the i-GO study. Voir source | 33243800 | 10.1136/bmjopen-2020-040162 | BMJ open | |
| Magnetic resonance imaging-guided ultrasound ablation for prostate cancer - A contemporary review of performance. Voir source | 36686753 | 10.3389/fonc.2022.1069518 | Frontiers in oncology | |
| Dystonia before and after Unilateral High Intensity Focused Ultrasound Thalamotomy in Essential and Dystonic Tremor. Voir source | 42463460 | 10.1002/mdc3.70743 | Movement disorders clinical practice | |
| Dual-approach High-intensity Focused Ultrasound for Facial Contour Modulation and Submental Reduction. Voir source | 42488921 | 10.1097/GOX.0000000000007919 | Plastic and reconstructive surgery. Global open | |
| Focal Therapy for Prostate Cancer: A Treatment Option Reserved for the Ideal Candi-date? Voir source | 42455608 | 10.1590/S1677-5538.IBJU.2026.0222 | International braz j urol : official journal of the Brazilian Society of Urology | |
| Oncologic and functional outcomes of novel focal therapy methods for low-risk to intermediate-risk prostate cancer. Voir source | 42489172 | 10.1097/MOU.0000000000001427 | Current opinion in urology | |
| Comparative study on the effects of high-intensity focused ultrasound (HIFU) and laparoscopic myomectomy on ovarian function and endometrial receptivity in patients with uterine fibroids. Voir source | 42544600 | 10.1080/02656736.2026.2703617 | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | |
| Safety, feasibility, and palliative benefit of HIFU combined with PD-1 inhibitors for elderly patients with advanced pancreatic cancer: a real-world retrospective study. Voir source | 42552867 | 10.1080/02656736.2026.2713171 | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | |
| Noninvasive treatment strategy for abdominal wall desmoid tumors applying high-intensity focused ultrasound. Voir source | 42563407 | 10.1080/02656736.2026.2662962 | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | |
| Fast lesion mapping during HIFU treatment using harmonic motion imaging guided focused ultrasound (HMIgFUS) in vitro and in vivo. Voir source | 28323638 | 10.1088/1361-6560/aa6024 | Physics in medicine and biology | |
| Application of high-intensity focused ultrasound in gynaecological diseases. Voir source | 41867046 | 10.1080/02656736.2026.2635294 | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | |
| Metabolic characteristic changes in local tissues after high-intensity focused ultrasound treatment for uterine fibroids. Voir source | 41846319 | 10.1080/02656736.2026.2639437 | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group |
Sources officielles
liens de rechercheDernière mise à jour des données : 2019-06-26
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.